Health and Economic Challenge of Adverse Drug Reactions in Children

The Unseen Burden: Pediatric ADRs in Europe

Adverse Drug Reactions in children pose a significant health and economic challenge.

Key Statistics at a Glance

€1.3B

Annual cost per country for hospital admissions due to ADRs.

4.1x

ADR incidence in children compared to adults.

74.4%

of Pediatric ADRs lead to death, disability or hospitalization.

39.3%

of PADRs causing hospital admissions were life-threatening.

European Initiatives on Healthcare Equity

💊

Pediatric Regulation

Encourage the development of medicines for pediatric use by requiring a Pediatric Investigation Plan (PIP).

🔎

Pharmacovigilance

Enhanced monitoring and reporting of adverse drug reactions with more comprehensive data collection.

🤝

Research Networks

ENPR-EMA network facilitates studies on medicines for children across Europe, including the c4c-S program.

Synoptic Intelligence: From Reactive to Proactive

Synoptic Intelligence enhances existing frameworks by identifying ADR signals that were undetectable in the past. This enables early risk detection and safe, personalized prescription.

Discover More

Explore how Synoptic Intelligence is revolutionizing pediatric drug safety and shaping the future of predictive healthcare.

Pediatric ADR Prediction

More to Explore

Rewriting the Rules of Pediatric Safety

The future of pediatric care isn’t coming — it’s already here. We’re introducing Synoptic Intelligence to break the bottleneck in EHR‑based AI and safeguard children from harmful, unintended consequences of medical treatment.

Synoptic AI Engine Excels in Medical Record Interpretation

Synoptic Intelligence Resolves Discrepancy in Clinical Statistics and Outperforms 20x Larger Language Model in EHR Interpretation

3 Takeaways from Our Media Coverage

How our deep learning outperforms prominent models in bioactivity prediction and empowers practical, scalable solutions in real world

True Acceleration Saves Much More than You May Have Imagined

A tenfold reduction of the time for lead optimization saves the development expenses by 15 folds. More savings can be expected when it comes in synergy with the reduction of research cost.